Are stock-market investors overpricing or underpricing a potential coronavirus


The stock market’s rally back to all-time highs might not have been possible without optimism over a COVID-19 vaccine. And that means progress and setbacks toward that goal could continue to drive the market in the weeks and months ahead.

Analysts at UBS rolled back the market tape to take a look at how stocks have reacted to positive and negative vaccine-related news since the coronavirus pandemic hit. They concluded that optimism around vaccine developments added around 6.5 percentage points to the S&P 500’s return since May.

If so, that certainly helped the S&P 500
SPX,
+0.34%

to take back the ground it lost during the stock market’s pandemic-inspired plunge. The U.S. benchmark closed at record highs this past week, including in Friday’s session, returning to trade above levels seen before falling nearly 34% from a Feb. 19 record to its March 23 low as the spread of COVID-19 forced the near-shutdown of the U.S. and global economy.

The UBS analysts calculated the impact by measuring the number of “shock” days, in which the S&P 500 moved up or down by at least one standard deviation versus its average daily movement in reaction to positive or negative vaccine-related news. Using their model, which gauges how much positive vaccine news contributed to a fall in a closely followed economic policy uncertainty index, they concluded that investors had priced in a 33% to 40% probability of a vaccine.

On an industry level, however, it appears prospects for a vaccine are less priced in, the analysts said. They noted that shares of companies with the most to gain — such as hard-hit hospitality and leisure stocks — from a vaccine have barely outperformed the S&P 500 since May, suggesting a vaccine isn’t really priced in across industries, they wrote.

Several companies are working toward a vaccine. The Wall Street Journal on Thursday reported that Johnson & Johnson
JNJ,
+0.88%

plans to launch what could be the largest clinical trial of a COVID-19 vaccine seen so far, enlisting up to 60,000 people world-wide. That would be double the size of other pivotal studies that have started or are expected to begin soon for vaccines developed by Moderna Inc.
MRNA,
-2.00%
,
Pfizer Inc.
PFE,
+0.41%

and AstraZeneca PLC
AZN,
-1.38%
.

Meanwhile, it might be small- and midcap stocks that would stand to benefit most from a vaccine breakthrough. The UBS analysts noted that small caps outperformed large-caps by around 2 percentage points on days when there was major vaccine news. If market participants currently see a 33% to 40% probability priced in for a vaccine, potential outperformance for small versus large-cap stocks stands at around 13 percentage points or more, they said.

The relative performance of value stocks relative to growth stocks, however, has been subdued, they said.

Cyclical stocks, which are more sensitive to the economic cycle, have solidly outperformed defensive stocks on days with big vaccine news, with even more variation at the industry and sub-industry level. UBS said that would indicate the potential for around 10 percentage points or more of outperformance by cyclicals over defensives if a vaccine is fully priced and implemented.

Analysts and investors have pointed to optimism over a vaccine as insulating the market from disappointment on other fronts, including the inability of congressional Democrats and Republicans and the White House to come up with a plan for another round of coronavirus aid. Economists warned that concerns about the economic damage caused by the pandemic could overshadow those hopes.

“Long-term optimism regarding a vaccine is secondary to near-term economic and health concerns: a jobs deficit of 13 million relative to pre-COVID, states facing budget crises, and still more than 50,000 daily COVID-19 infections,” said Gregory Daco, chief U.S. economist at Oxford Economics, in a Friday note.

The S&P 500 rose 0.7% over the last week, with Friday’s close at a record 3,397.16. The Dow Jones Industrial Average
DJIA,
+0.68%

was virtually flat on the week, finishing at 27,930.33, while the tech-heavy Nasdaq Composite
COMP,
+0.41%

saw a weekly advance of 2.7%, closing Friday at 11,311.80, its 36th record finish of 2020.

Economic data on tap in the week ahead include July durable goods orders, due on Wednesday, and personal income and consumption data on Friday. The main event might once again come on Thursday with the release of weekly data on jobless claims, after first-time applications for benefits in the latest week pushed back above 1 million, raising concerns about prospects for a continued recovery in the labor market.



Read More: Are stock-market investors overpricing or underpricing a potential coronavirus

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.